Archive for Articles

Weekly Summary of key pharma events – week ended January 6 2012

Jan 07, 2012 No Comments

See individual posts made in the last week for more detail. PDUFA/NDA FILINGS/ADVISORY COMMITTEE NEWS AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) said that it intends to file its NDA for tivozanib during 2012 following full data release at ASCO this year. Cornerstone Therapeutics (NASDAQ: CRTX) – NDA for lixivaptan for the treatment of hyponatremia was filed on Dec. 29, […]

Read more

Merry Xmas – Summary of pharma events week ending 12/23/12

Dec 23, 2011 No Comments

A Merry Xmas to all readers of BioPharmCatalyst. Thank you all for your support over the past year and wish you all a relaxing break with friends and family! See individual posts made in the last week for more detail.   PDUFA/FDA RELATED EVENTS Santarus, Inc. (NASDAQ: SNTS) submitted its NDA for UCERIS for mild to […]

Read more

Companies facing NASDAQ delist or reverse splits in 2012

Dec 23, 2011 No Comments

If companies are unable to push their bid price above $1 they either face delisting from NASDAQ to OTCBB or will require a reverse split to remain on NASDAQ. Most of the companies below face no meaningful upcoming catalysts to propel their bid price above $1. Which companies are in this category? I have 10 […]

Read more

A look back at reverse split and NASDAQ-delist projections made in August 2011

Dec 22, 2011 No Comments

On August 1, 2011, I listed seven companies facing NASDAQ delist or a reverse split to remain listed on NASDAQ. I now follow up the list by firstly noting my prediction, then what actually happened. You can read the original post HERE and results of other projections HERE. (First bracket indicates price as of August […]

Read more

Weekly Summary of key pharma events – week ended 12/16/11

Dec 17, 2011 No Comments

See individual posts made in the last week for more detail. PDUFA/FDA RELATED EVENTS NeurogesX, Inc. (Nasdaq:NGSX) will meet with the FDA Anesthetic and Analgesic Drug Products Advisory Committee on February 9, 2012 to discuss the available efficacy and safety data for sNDA of QUTENZA for the management of neuropathic pain related to HIV-associated peripheral neuropathy. Isis Pharmaceuticals, […]

Read more

Weekly Summary of key pharma events – week ended 12/9/11

Dec 10, 2011 No Comments

Affymax, Inc. (Nasdaq:AFFY) received positive recommendation from the FDA Oncologic Drugs Advisory Committee (ODAC) for its  New Drug Application (NDA) of peginesatide for the proposed treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis was reviewed. The panel was asked to consider the following question, “Considering the safety issues associated with […]

Read more

Welcome to the new BioPharmCatalyst!

Dec 05, 2011 5 Comments

Welcome all readers to the third and new version of BioPharmCatalyst. While the two previous versions since the initial launch in June 2010 have had many tools available for readers in their investment decisions, I have always been of the opinion that the data on the site could be presented in a much greater user […]

Read more

7 companies facing upcoming reverse splits or NASDAQ delist

Aug 01, 2011 No Comments

If companies are unable to push their bid price above $1 they either face delisting from NASDAQ to OTCBB or will require a reverse split to remain on NASDAQ. Most of the companies below face no meaningful upcoming catalysts to propel their bid price above $1. Which companies are in this category? I have 7 […]

Read more

A look back on predictions made in February of 1H 2011 reverse splits

Jul 29, 2011 No Comments

On February 14, 2011, I listed about a dozen companies facing delist from NASDAQ or a reverse split to remain listed on NASDAQ during 1H 2011. I now follow up the list by firstly noting my prediction, then what actually happened. (First bracket indicates price as of FEBRUARY 14) – (Second bracket indicates price REVERSE SPLIT […]

Read more

Upcoming votes for Reverse Splits and to increase Authorised Shares

May 24, 2011 No Comments

Over the next month or so, many companies will be holding shareholder meetings to vote on various issues such as electing directors or making adjustments to Equity Incentive plans. However, some companies also use the meetings to request permission to increase the number of Authorised Shares and to enforce Reverse Splits. It should be noted […]

Read more

ASCO 2011 Abstracts have been added to the ASCO Calendar

May 19, 2011 No Comments

The BioPharmCatalyst ASCO 2011 Calendar has been completed with the addition of ALL abstracts of companies that were originally listed on the calendar. Just click on the ASCO tab above and you will find that abstracts have been added by clicking on the Abstract Link number. There are many companies that are just presenting previously […]

Read more